Information:
Error:
ID
13019
Description
Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome; ODM derived from: https://clinicaltrials.gov/show/NCT00004263
Link
https://clinicaltrials.gov/show/NCT00004263
Keywords
Versions (1)
- 1/12/16 1/12/16 -
Copyright Holder
CC BY-NC 3.0
Uploaded on
January 12, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Leukemia NCT00004263
Eligibility Leukemia NCT00004263
- StudyEvent: Eligibility
Similar models
Eligibility Leukemia NCT00004263
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
relapsed acute myelogenous leukemia, or myelodysplastic syndromes
Item
1. 1. patients with refractory or relapsed acute myelogenous leukemia, or myelodysplastic syndromes (raeb or raeb-t).
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2])
C3463824 (UMLS CUI [2])
performance status
Item
2. 2. performance status of =< 2
boolean
C1518965 (UMLS CUI [1])
informed consent
Item
3. 3. signed informed consent indicating that patients are aware of the investigational nature of this study in keeping with the policies of the hospital. the only acceptable consent form is the one attached at the end of this protocol for each participating institution.
boolean
C0021430 (UMLS CUI [1])
chemotherapy
Item
4. 4. patients must have been off chemotherapy for 2 weeks prior to entering this study and recovered from the toxic effects of that therapy, unless there is evidence of rapidly progressive disease.
boolean
C0392920 (UMLS CUI [1])
bilirubin and creatinine
Item
5. 5. bilirubin and creatinine (or creatinine clearance) should be within institutional normal limits.
boolean
C1278039 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C0201976 (UMLS CUI [2])
high-dose ara-c-based (>=1g/m2/day x 3 days) chemotherapy
Item
6. 6. patients must have relapsed or failed to respond after high-dose ara-c-based (>=1g/m2/day x 3 days) chemotherapy.
boolean
C0010711 (UMLS CUI [1])
DLCO
Item
7. 7. corrected dlco >50%.
boolean
C1516251 (UMLS CUI [1])
cardiac risk factors
Item
8. 8. patients with >=3 cardiac risk factors (smoking, hypertension, family history of coronary artery disease, diabetes mellitus, hypercholesterolemia) should have a nuclear medicine stress test.
boolean
C2024776 (UMLS CUI [1])
pregnancy
Item
1. 1. the anti-proliferative activity of the experimental drug may be harmful to the developing fetus or nursing infant. therefore, pregnant and nursing females will be excluded. patients of childbearing potential should practice effective methods of contraception.
boolean
C0032961 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
allogeneic marrow transplant
Item
2. 2. patients who are eligible for allogeneic marrow transplant and who have a donor will be offered transplant.
boolean
C0149615 (UMLS CUI [1])
comorbidity or radiotherapy
Item
3. 3. patients with existing pulmonary diseases, history of coronary artery disease or who have received radiotherapy to the mediastinum.
boolean
C0009488 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C1522449 (UMLS CUI [2])